Compare DAVA & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAVA | RZLT |
|---|---|---|
| Founded | 2000 | 2010 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 365.7M | 326.4M |
| IPO Year | 2015 | 2011 |
| Metric | DAVA | RZLT |
|---|---|---|
| Price | $5.31 | $3.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | ★ $14.57 | $9.17 |
| AVG Volume (30 Days) | 528.3K | ★ 2.4M |
| Earning Date | 01-01-0001 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.26 | N/A |
| P/E Ratio | $20.02 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.38 | $1.07 |
| 52 Week High | $23.71 | $11.46 |
| Indicator | DAVA | RZLT |
|---|---|---|
| Relative Strength Index (RSI) | 49.49 | 48.78 |
| Support Level | $4.85 | $2.80 |
| Resistance Level | $7.04 | $4.21 |
| Average True Range (ATR) | 0.39 | 0.32 |
| MACD | 0.06 | -0.01 |
| Stochastic Oscillator | 67.52 | 29.74 |
Endava is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2006 in the UK, and it continues to generate the majority of revenue in the UK and Europe. Endava's client base is concentrated in the payments and financial services, technology, media, and telecom industries.
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.